Quintiles And Eisai Collaborate To Develop Cancer Compounds
This article was originally published in PharmAsia News
Executive SummaryMoving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30
You may also be interested in...
Eisai’s lenvatinib achieved proof of concept for melanoma, and now Eisai steps back into the picture for Phase III.
Pfizer Inc. and Eisai Co.'s downsized R&D budgets seek no-risk solutions with SFJ Pharma.